The osteocyte as a therapeutic target in the treatment of osteoporosis

Therapeutic Advances in Musculoskeletal Disease

Volumn 6, Issue 3, 2014, Pages 79-91

  Rochefort, Gaël Y ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

drug therapy; osteocyte; osteoporosis

Indexed keywords

ALENDRONIC ACID; DICKKOPF 1 PROTEIN; G PROTEIN COUPLED RECEPTOR; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ROMOSOZUMAB; SCLEROSTIN; TESTOSTERONE; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; BONE TURNOVER; FRACTURE; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; NONHUMAN; OSSIFICATION; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WNT SIGNALING PATHWAY;

EID: 84901724058     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X14523500     Document Type: Review

References (134)

1. Agholme F. Isaksson H. Kuhstoss S. Aspenberg P. (2011) The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 48: 988–996.
2. Ahn V. Chu M. Choi H. Tran D. Abo A. Weis W. (2011) Structural basis of Wnt signaling inhibition by Dickkopf binding to LRP5/6. Dev Cell 21: 862–873.
3. Aspenberg P. (2006) Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf 5: 743–745.
4. Atchison D. Harding P. Beierwaltes W. (2011) Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension 58: 604–610.
5. Aubin J. Turksen K. (1996) Monoclonal antibodies as tools for studying the osteoblast lineage. Microsc Res Tech 33: 128–140.
6. Avlani V. Ma W. Mun H. Leach K. Delbridge L. Christopoulos A. et al. (2013) Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK 293 cells and human parathyroid cells. Am J Physiol Endocrinol Metab 304: E1097–E1104.
7. Balan G. Bauman J. Bhattacharya S. Castrodad M. Healy D. Herr M. et al. (2009) The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett 19: 3328–3332.
8. Balemans W. Ebeling M. Patel N. van Hul E. Olson P. Dioszegi M. et al. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537–543.
9. Banumathy G. Cairns P. (2010) Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10: 658–664.
10. Baron R. Kneissel M. (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19: 179–192.
11. Bellido T. Ali A. Gubrij I. Plotkin L. Fu Q. O'Brien C. et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577–4583.
12. Bellido T. Saini V. Pajevic P. (2013) Effects of PTH on osteocyte function. Bone 54: 250–257.
13. Bhadada S. Rastogi A. Steenackers E. Boudin E. Arya A. Dhiman V. et al. (2013) Novel SOST gene mutation in a sclerosteosis patient and her parents. Bone 52: 707–710.
14. Bivi N. Nelson M. Faillace M. Li J. Miller L. Plotkin L. (2012) Deletion of Cx 43 from osteocytes results in defective bone material properties but does not decrease extrinsic strength in cortical bone. Calcif Tissue Int 91: 215–224.
15. Blake G. Fogelman I. (2007) Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 10: 102–110.
16. Bonewald L. (2011) The amazing osteocyte. J Bone Miner Res 26: 229–238.
17. Boudin E. Fijalkowski I. Piters E. van Hul W. (2013) The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin Arthritis Rheum 43: 220–240.
18. Bourhis E. Tam C. Franke Y. Bazan J. Ernst J. Hwang J. et al. (2010) Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk 1 binding sites on LRP6. J Biol Chem 285: 9172–9179.
19. Bringhurst F. (2002) PTH receptors and apoptosis in osteocytes. J Musculoskelet Neuronal Interact 2: 245–251.
20. Brown E. (2007) The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 45: 139–167.
21. Brunkow M. Gardner J. van Ness J. Paeper B. Kovacevich B. Proll S. et al. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577–589.
22. Bu G. Lu W. Liu C. Selander K. Yoneda T. Hall C. et al. (2008) Breast cancer-derived Dickkopf 1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 123: 1034–1042.
23. Burra S. Nicolella D. Francis W. Freitas C. Mueschke N. Poole K. et al. (2010) Dendritic processes of osteocytes are mechanotransducers that induce the opening of hemichannels. Proc Natl Acad Sci U S A 107: 13648–13653.
24. Cabal A. Mehta K. Ross D. Shrestha R. Comisar W. Denker A. et al. (2013) A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans. J Bone Miner Res 28: 1830–1836.
25. Choi H. Dieckmann M. Herz J. Niemeier A. (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PloS ONE 4: e7930.
26. Cohen-Kfir E. Artsi H. Levin A. Abramowitz E. Bajayo A. Gurt I. et al. (2011) Sirt 1 is a regulator of bone mass and a repressor of SOST encoding for sclerostin, a bone formation inhibitor. Endocrinology 152: 4514–4524.
27. Cook F. Mumm S. Whyte M. Wenkert D. (2013) Pregnancy-associated osteoporosis with a heterozygous deactivating LDL receptor-related protein 5 (LRP5) mutation and a homozygous methylenetetrahydrofolate reductase (MTHFR) polymorphism. J Bone Miner Res. [Epub ahead of print]
28. Cui L. Cheng H. Song C. Li C. Simonet W. Ke H. et al. (2013) Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact 13: 178–184.
29. Daci E. van Cromphaut S. Bouillon R. (2002) Mechanisms influencing bone metabolism in chronic illness. Horm Res 58(Suppl. 1): 44–51.
30. Dallas S. Prideaux M. Bonewald L. (2013) The osteocyte: an endocrine cell … and more. Endocr Rev 34: 658–690.
31. Deal C. (2009) Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 5: 20–27.
32. Devogelaer J. (2000) Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 12: 331–335.
33. Diarra D. Stolina M. Polzer K. Zwerina J. Ominsky M. Dwyer D. et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156–163.
34. Eddleston A. Marenzana M. Moore A. Stephens P. Muzylak M. Marshall D. et al. (2009) A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 24: 1662–1671.
35. Ellwanger K. Saito H. Clement-Lacroix P. Maltry N. Niedermeyer J. Lee W. et al. (2008) Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol 28: 4875–4882.
36. Ettenberg S. Charlat O. Daley M. Liu S. Vincent K. Stuart D. et al. (2010) Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP 6 antibodies. Proc Natl Acad Sci U S A 107: 15473–15478.
37. Fitzpatrick L. Dabrowski C. Cicconetti G. Gordon D. Fuerst T. Engelke K. et al. (2012) Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 27: 255–262.
38. Fleisch H. (2002) Development of bisphosphonates. Breast Cancer Res 4: 30–34.
39. Fraher L. Avram R. Watson P. Hendy G. Henderson J. Chong K. et al. (1999) Comparison of the biochemical responses to human parathyroid hormone-(1–31)NH2 and hPTH-(1–34) in healthy humans. J Clin Endocrinol Metab 84: 2739–2743.
40. Fraser W. Ahmad A. Vora J. (2004) The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis. Curr Opin Nephrol Hypertens 13: 437–444.
41. Fromigue O. Hay E. Barbara A. Petrel C. Traiffort E. Ruat M. et al. (2009) Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med 13: 2189–2199.
42. Fulciniti M. Tassone P. Hideshima T. Vallet S. Nanjappa P. Ettenberg S. et al. (2009) Anti-DKK1 m Ab (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371–379.
43. Gamie Z. Korres N. Leonidou A. Gray A. Tsiridis E. (2012) Sclerostin monoclonal antibodies on bone metabolism and fracture healing. Expert Opin Investig Drugs 21: 1523–1534.
44. Garnero P. (2008) Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 12: 157–170.
45. Gaudio A. Privitera F. Battaglia K. Torrisi V. Sidoti M. Pulvirenti I. et al. (2012) Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97: 3744–3750.
46. Glantschnig H. Hampton R. Lu P. Zhao J. Vitelli S. Huang L. et al. (2010) Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 285: 40135–40147.
47. Glantschnig H. Scott K. Hampton R. Wei N. Mccracken P. Nantermet P. et al. (2011) A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J Pharmacol Exp Ther 338: 568–578.
48. Gong Y. Bourhis E. Chiu C. Stawicki S. Dealmeida V. Liu B. et al. (2010) Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP 6 antibodies. PloS ONE 5: e12682.
49. Guder C. Pinho S. Nacak T. Schmidt H. Hobmayer B. Niehrs C. et al. (2006) An ancient Wnt-Dickkopf antagonism in Hydra. Development 133: 901–911.
50. Heino T. Kurata K. Higaki H. Vaananen H. (2009) Evidence for the role of osteocytes in the initiation of targeted remodeling. Technol Health Care 17: 49–56.
51. Henriksen K. Andersen J. Riis B. Mehta N. Tavakkol R. Alexandersen P. et al. (2013) Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH (2)] in postmenopausal women with osteoporosis. Bone 53: 160–166.
52. Hoeppner L. Secreto F. Westendorf J. (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13: 485–496.
53. Hoey D. Kelly D. Jacobs C. (2011) A role for the primary cilium in paracrine signaling between mechanically stimulated osteocytes and mesenchymal stem cells. Biochem Biophys Res Commun 412: 182–187.
54. Hopkins R. Tarride J. Leslie W. Metge C. Lix L. Morin S. et al. (2013) Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporos Int 24: 581–593.
55. John M. Widler L. Gamse R. Buhl T. Seuwen K. Breitenstein W. et al. (2011) ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone 49: 233–241.
56. Ke H. Richards W. Li X. Ominsky M. (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33: 747–783.
57. Keller H. Kneissel M. (2005) SOST is a target gene for PTH in bone. Bone 37: 148–158.
58. Khan A. Khan A. (2006) Anabolic agents: a new chapter in the management of osteoporosis. J Obstet Gynaecol Can 28: 136–141.
59. Khosla S. Burr D. Cauley J. Dempster D. Ebeling P. Felsenberg D. et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479–1491.
60. Killock D. (2011) Bone: osteocyte RANKL in bone homeostasis: a paradigm shift? Nat Rev Rheumatol 7: 619.
61. Kim J. Leucht P. Lam K. Luppen C. Ten Berge D. Nusse R. et al. (2007) Bone regeneration is regulated by wnt signaling. J Bone Miner Res 22: 1913–1923.
62. Klein-Nulend J. Nijweide P. Burger E. (2003) Osteocyte and bone structure. Curr Osteoporos Rep 1: 5–10.
63. Klein-Nulend J. Sterck J. Semeins C. Lips P. Joldersma M. Baart J. et al. (2002) Donor age and mechanosensitivity of human bone cells. Osteoporos Int 13: 137–146.
64. Kogianni G. Noble B. (2007) The biology of osteocytes. Curr Osteoporos Rep 5: 81–86.
65. Lavi-Moshayoff V. Wasserman G. Meir T. Silver J. Naveh-Many T. (2010) PTH increases FGF 23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882–F889
66. Lee D. Kim H. Ku S. Kim S. Choi Y. Kim J. (2010) Association between polymorphisms in Wnt signaling pathway genes and bone mineral density in postmenopausal Korean women. Menopause 17: 1064–1070.
67. Lengfeld T. Watanabe H. Simakov O. Lindgens D. Gee L. Law L. et al. (2009) Multiple Wnts are involved in Hydra organizer formation and regeneration. Dev Biol 330: 186–199.
68. Leupin O. Piters E. Halleux C. Hu S. Kramer I. Morvan F. et al. (2011) Bone overgrowth-associated mutations in the LRP 4 gene impair sclerostin facilitator function. J Biol Chem 286: 19489–19500.
69. Lewiecki E. (2013) Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther 13: 183–196.
70. Li D. Shao L. Zhou H. Jiang W. Zhang W. Xu Y. (2013) The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine 43: 68–77.
71. Li J. Sarosi I. Cattley R. Pretorius J. Asuncion F. Grisanti M. et al. (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39: 754–766.
72. Li X. Grisanti M. Fan W. Asuncion F. Tan H. Dwyer D. et al. (2011) Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26: 2610–2621.
73. Li X. Ominsky M. Warmington K. Morony S. Gong J. Cao J. et al. (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578–588.
74. Li X. Warmington K. Niu Q. Asuncion F. Barrero M. Grisanti M. et al. (2010 a) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25: 2647–2656.
75. Li Y. Pawlik B. Elcioglu N. Aglan M. Kayserili H. Yigit G. et al. (2010 b) LRP 4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani–Lenz syndrome. Am J Hum Genet 86: 696–706.
76. Lim V. Clarke B. (2012) New therapeutic targets for osteoporosis: beyond denosumab. Maturitas 73: 269–272.
77. Lindsay R. (1996) The menopause and osteoporosis. Obstet Gynecol 87: 16S-19S.
78. Liu C. Tu Y. Sun X. Jiang J. Jin X. Bo X. et al. (2011) Wnt/beta-catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 11: 105–112.
79. Lucero O. Dawson D. Moon R. Chien A. (2010) A re-evaluation of the “oncogenic” nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12: 314–318.
80. Maclean C. Newberry S. Maglione M. Mcmahon M. Ranganath V. Suttorp M. et al. (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148: 197–213.
81. Maeda A. Okazaki M. Baron D. Dean T. Khatri A. Mahon M. et al. (2013) Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A 110: 5864–5869.
82. Mao B. Wu W. Davidson G. Marhold J. Li M. Mechler B. et al. (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417: 664–667.
83. Marenzana M. Greenslade K. Eddleston A. Okoye R. Marshall D. Moore A. et al. (2011) Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 63: 2385–2395.
84. Moester M. Papapoulos S. Lowik C. van Bezooijen R. (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87: 99–107.
85. Moriishi T. Fukuyama R. Ito M. Miyazaki T. Maeno T. Kawai Y. et al. (2012) Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and SOST in osteocytes at unloading. PloS ONE 7: e40143.
86. Mosley J. (2000) Osteoporosis and bone functional adaptation: mechanobiological regulation of bone architecture in growing and adult bone, a review. J Rehabil Res Dev 37: 189–199.
87. Moustafa A. Sugiyama T. Prasad J. Zaman G. Gross T. Lanyon L. et al. (2012) Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int 23: 1225–1234.
88. Mulcahy L. Taylor D. Lee T. Duffy G. (2011) RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. Bone 48: 182–188.
89. Nakashima T. Hayashi M. Fukunaga T. Kurata K. Oh-Hora M. Feng J. et al. (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17: 1231–1234.
90. Nemeth E. (2004) Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium 35: 283–289.
91. O'Brien C. Plotkin L. Galli C. Goellner J. Gortazar A. Allen M. et al. (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PloS ONE 3: e2942.
92. Ohyama Y. Nifuji A. Maeda Y. Amagasa T. Noda M. (2004) Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 145: 4685–4692.
93. Ozcivici E. Luu Y. Adler B. Qin Y. Rubin J. Judex S. et al. (2010) Mechanical signals as anabolic agents in bone. Nat Rev Rheumatol 6: 50–59.
94. Padhi D. Jang G. Stouch B. Fang L. Posvar E. (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19–26.
95. Papapoulos S. (2011) Targeting sclerostin as potential treatment of osteoporosis. Ann Rheum Dis 70(Suppl. 1): i119–i122.
96. Post T. Schmidt S. Peletier L. de Greef R. Kerbusch T. Danhof M. (2013) Application of a mechanism-based disease systems model for osteoporosis to clinical data. J Pharmacokinet Pharmacodyn 40: 143–156.
97. Riccardi D. (2012) Antagonizing the calcium-sensing receptor: towards new bone anabolics? Curr Mol Pharmacol 5: 182–188.
98. Rizzoli R. Burlet N. Cahall D. Delmas P. Eriksen E. Felsenberg D. et al. (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42: 841–847.
99. Robling A. Niziolek P. Baldridge L. Condon K. Allen M. Alam I. et al. (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283: 5866–5875.
100. Rochefort G. Benhamou C. (2013) Osteocytes are not only mechanoreceptive cells. Int j numer method biomed eng 29: 1082–1088.
101. Rochefort G. Pallu S. Benhamou C. (2010) Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 21: 1457–1469.
102. Rosser J. Bonewald L. (2012) Studying osteocyte function using the cell lines MLO-Y4 and MLO-A5. Methods Mol Biol 816: 67–81.
103. Rybchyn M. Slater M. Conigrave A. Mason R. (2011) An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. J Biol Chem 286: 23771–23779.
104. Sassi N. Laadhar L. Allouche M. Zandieh-Doulabi B. Hamdoun M. Klein-Nulend J. et al. (2013) The roles of canonical and non-canonical Wnt signaling in human de-differentiated articular chondrocytes. Biotech Histochem 13: 384–392.
105. Schilcher J. Michaelsson K. Aspenberg P. (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364: 1728–1737.
106. Schnatz P. Marakovits K. O'Sullivan D. (2010) Assessment of postmenopausal women and significant risk factors for osteoporosis. Obstet Gynecol Surv 65: 591–596.
107. Scholer-Dahirel A. Schlabach M. Loo A. Bagdasarian L. Meyer R. Guo R. et al. (2011) Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 108: 17135–17140.
108. Schulze J. Seitz S. Saito H. Schneebauer M. Marshall R. Baranowsky A. et al. (2010) Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PloS ONE 5: e10309.
109. Shankar Y. Misra S. Vineet D. Baskaran P. (2013) Paget disease of bone: a classic case report. Contemp Clin Dent 4: 227–230.
110. Shoback D. (2007) Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab 92: 747–753.
111. Simon-Chazottes D. Tutois S. Kuehn M. Evans M. Bourgade F. Cook S. et al. (2006) Mutations in the gene encoding the low-density lipoprotein receptor LRP 4 cause abnormal limb development in the mouse. Genomics 87: 673–677.
112. Sinder B. Eddy M. Ominsky M. Caird M. Marini J. Kozloff K. (2013) Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28: 73–80.
113. Staehling-Hampton K. Proll S. Paeper B. Zhao L. Charmley P. Brown A. et al. (2002) A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 110: 144–152.
114. Sun G. Guo T. Chen Y. Xu B. Guo J.H. Zhao J. (2013) Significant pathways detection in osteoporosis based on the bibliometric network. Eur Rev Med Pharmacol Sci 17: 1–7.
115. Svedlund J. Auren M. Sundstrom M. Dralle H. Akerstrom G. Bjorklund P. et al. (2010) Aberrant WNT/beta-catenin signaling in parathyroid carcinoma. Mol Cancer 9: 294.
116. Taxel P. Kenny A. (2000) Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone 2: 11–21.
117. Tian X. Jee W. Li X. Paszty C. Ke H. (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48: 197–201.
118. Trivedi R. Mithal A. Chattopadhyay N. (2008) Recent updates on the calcium-sensing receptor as a drug target. Curr Med Chem 15: 178–186.
119. Tsuruta Y. Okano K. Kikuchi K. Akiba T. Nitta K. (2013) Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 17: 120–126.
120. Uderhardt S. Diarra D. Katzenbeisser J. David J. Zwerina J. Richards W. et al. (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69: 592–597.
121. Uitterlinden A. Arp P. Paeper B. Charmley P. Proll S. Rivadeneira F. et al. (2004) Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet 75: 1032–1045.
122. Uzbekov R. Maurel D. Aveline P. Pallu S. Benhamou C. Rochefort G. (2012) Centrosome fine ultrastructure of the osteocyte mechanosensitive primary cilium. Microsc Microanal 18: 1430–1441.
123. van Bezooijen R. Roelen B. Visser A. van der Wee-Pals L. de Wilt E. Karperien M. et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805–814.
124. van Bezooijen R. Ten Dijke P. Papapoulos S. Lowik C. (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16: 319–327.
125. van der Lee M. Verkaar F. Wat J. van Offenbeek J. Timmerman M. Voorneveld L. et al. (2013) Beta-arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor. Cell Signal 25: 527–538.
126. van Dinther M. Zhang J. Weidauer S. Boschert V. Muth E. Knappik A. et al. (2013) Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt/LRP6 signaling. PloS ONE 8: e62295.
127. van Lierop A. Hamdy N. Hamersma H. van Bezooijen R. Power J. Loveridge N. et al. (2011) Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26: 2804–2811.
128. Verborgt O. Gibson G. Schaffler M. (2000) Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 15: 60–67.
129. Wang Y. Liu Y. Rowe D. (2007) Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am J Physiol Endocrinol Metab 292: E594–E603.
130. Whitfield J. (2006) Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How might they do it? Curr Opin Investig Drugs 7: 349–359.
131. Winkler D. Sutherland M. Geoghegan J. Yu C. Hayes T. Skonier J. et al. (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267–6276.
132. Xue Y. Xiao Y. Liu J. Karaplis A. Pollak M. Brown E. et al. (2012) The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab 302: E841–E851.
133. Yang D. Singh R. Divieti P. Guo J. Bouxsein M. Bringhurst F. (2007) Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 40: 1453–1461.
134. Yu X. Wang Y. Degraff D. Wills M. Matusik R. (2011) Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30: 1868–1879.